1173 related articles for article (PubMed ID: 28216140)
1. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
2. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
[TBL] [Abstract][Full Text] [Related]
3. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
4. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
6. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
[TBL] [Abstract][Full Text] [Related]
7. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma.
Huhta H; Helminen O; Lehenkari PP; Saarnio J; Karttunen TJ; Kauppila JH
Oncotarget; 2016 Apr; 7(17):23658-67. PubMed ID: 27008696
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pages C; Paraf F; Dubois S; Belghiti J; Fléjou JF
Histopathology; 1998 Jan; 32(1):7-14. PubMed ID: 9522210
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
13. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia.
Wang DH; Clemons NJ; Miyashita T; Dupuy AJ; Zhang W; Szczepny A; Corcoran-Schwartz IM; Wilburn DL; Montgomery EA; Wang JS; Jenkins NA; Copeland NA; Harmon JW; Phillips WA; Watkins DN
Gastroenterology; 2010 May; 138(5):1810-22. PubMed ID: 20138038
[TBL] [Abstract][Full Text] [Related]
14. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
15. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker.
Turner JR; Odze RD; Crum CP; Resnick MB
Hum Pathol; 1997 Jun; 28(6):740-4. PubMed ID: 9191010
[TBL] [Abstract][Full Text] [Related]
16. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
17. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
18. DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma.
Thanan R; Ma N; Hiraku Y; Iijima K; Koike T; Shimosegawa T; Murata M; Kawanishi S
Mediators Inflamm; 2016; 2016():7937814. PubMed ID: 27069317
[TBL] [Abstract][Full Text] [Related]
19. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Schmidt MK; Meurer L; Volkweis BS; Edelweiss MI; Schirmer CC; Kruel CD; Gurski RR
Dis Esophagus; 2007; 20(3):212-6. PubMed ID: 17509117
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
